ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2478

Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2356

Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1837

Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1906

Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2518

Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 2402

Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2365

Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2348

Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2352

Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2368

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1794

Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2523

Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 2387

Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1806

Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2420

Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III

«Previous Page
1
…
7
8
9
10
11
…
61
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].